Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00127920|
Recruitment Status : Completed
First Posted : August 9, 2005
Last Update Posted : March 10, 2015
The most likely way to improve survival and cure rates in treating ovarian cancer, fallopian tube epithelial cancer, and peritoneal cancer is with maximal "upfront" therapy (Morrow & Curtin, 1998). This involves an optimal primary tumor debulking surgery. The most active chemotherapy agents should then be promptly administered. Taxol and Carboplatin or Cisplatin have become the standard" first line" therapy because of proven survival benefits with those regimens in treating advanced ovarian adenocarcinoma patients. New chemotherapy agents like bevacizumab have demonstrated increased overall and progression free survival benefits in metastatic colorectal cancer patients and are being studied for their potential contributory impact on the current standard of treatment. Since no triplet regimen has demonstrated compelling superiority, the combination of taxol, carboplatin, and bevacizumab is intriguing because of their potential synergy, distinct mechanisms of action, and non-overlapping toxicity.
The null hypothesis (Ho) is that the drug regimen will demonstrate an 80% patient response rate (RR).
The alternative Hypothesis (H1): The triplet drug regimen will demonstrate a significantly higher patient response rate than standard therapy.
Hypothesis (H2): The triplet drug regimen will demonstrate a significantly more favorable patient time to tumor progression rate than standard therapy.
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Neoplasms||Drug: Avastin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II, Open-Label, Non-Randomized, Multi-Center Pilot Study of Intravenous Taxol, Carboplatin, Bevacizumab Given Every 21 Days in Patients With Newly Diagnosed Stage III/IV Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer|
|Study Start Date :||August 2004|
|Actual Primary Completion Date :||August 2006|
|Actual Study Completion Date :||October 2012|
Experimental: Single Arm
Paclitaxel, Carboplatin and Avastin on day1 every 21 days
Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
Other Name: Bevacizumab
- time to tumor progression
- response rate
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00127920
|United States, California|
|Gynecologic Oncology Associates|
|Newport Beach, California, United States, 92663|
|United States, Florida|
|Florida Hospital College of Health Sciences|
|Orlando, Florida, United States, 32803|
|Principal Investigator:||John P Micha, MD||Gynecologic Oncology Associates|